The ocular side effects of vigabatrin (Sabril): Information and guidance for screening

Eye

Volumn 22, Issue 9, 2008, Pages 1097-1098

  Hawker, M J ^a   Astbury, N J ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG WITHDRAWAL; EDITORIAL; EPILEPSY; EVOKED VISUAL RESPONSE; HIGH RISK POPULATION; HUMAN; PERIMETRY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; RELIABILITY; RETINA DEGENERATION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; VISUAL FIELD CONSTRICTION; VISUAL FIELD DEFECT;

EID: 52149089498     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.139     Document Type: Editorial

References (14)

1. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314(7075): 180-181.
2. Ackers R, Murray ML, Besag FM, Wong IC. Prioritizing children's medicines for research: A pharmacoepidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007; 63(6): 689-697.
3. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106(9): 1792-1798.
4. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2006; 47(3): 917-924.
5. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67(6): 716-722.
6. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M et al. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings. Neurology 1999; 53(9): 2082-2087.
7. Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E et al. Vigabatrin and epilepsy: Lessons learned. Epilepsia 2007; 48 (7): 1318-1327.
8. Kalviainen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15 (3): 217-230.
9. Harding GF, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss. Neurology 2000; 55(3): 347-352.
10. Harding GF, Robertson KA, Edson AS, Barnes P, Wild J. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol 1998; 97(2): 179-188.
11. Harding GF, Spencer EL, Wild JM, Conway M, Bohn RL. Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children. Neurology 2002; 58(8): 1261-1265.
12. Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001; 42(5): 609-615.
13. Lawden MC. Vigabatrin-associated visual field constriction: A review. Optometry Pract 2006; 7: 1-14.
14. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 2000; 84 (7): 788-790.